TMEM258

Across TCGA pan-cancer cohorts, TMEM258 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM258 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM258 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM258 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where TMEM258 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.857	0.556	.004	38	view →
LUAD	OS	Median	III,IV	0.772	0.219	.003	17	view →
LSCC	DFS	Median	All	0.884	0.999	.004	10	view →
PDAC	OS	Median	IV	0.395	0.934	.024	8	view →
GBM	OS	Median	All	0.495	0.273	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM258–HNSC (DFS)

Open the HNSC breakdown →